<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298075</url>
  </required_header>
  <id_info>
    <org_study_id>ITP0714</org_study_id>
    <nct_id>NCT02298075</nct_id>
  </id_info>
  <brief_title>Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia</brief_title>
  <official_title>Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is the evaluation of sustained response rate after
      discontinuation of treatment with TPO-RAs, Eltrombopag and Romiplostim, in persistent or
      chronic pITP patients who failed one or more therapy lines, splenectomy included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing evidence exists in the literature on the persistent response after TPO-RAs
      discontinuation. However, the available data consist of description of case reports from
      different patients' series. At this time, systematic data collections on this topic do not
      exist and the real incidence of such persistent response is unknown. Therefore, because of
      the increasing interest in this new and challenging therapeutic field, also for the
      therapeutic implications, we would like to investigate the impact of TPO- RAs on the
      achievement of sustained and persistent responses after their discontinuation in the Italian
      adult patients affected by pITP who have been referred to the GIMEMA Centers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of sustained response rate after discontinuation of treatment with TPO-RAs in terms of patients still alive in Complete Response or R at more than 4 weeks after discontinuation.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of the type of response in patients treated with TPO-RAs in absence of concomitant or rescue medication, in order to estimate the rate of Response (R) and Complete Response (CR).</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the suspension criteria in terms of frequency of discontinuation causes for each center.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the duration of sustained response in terms of patients alive in CR or R at 6 and 12 months after sustained response achievement.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of incidence of relapse and loss of response at 6 and 12 months after sustained response achievement.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of treatment duration starting from the date of first dose of TPO-RAs.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Platelet levels and TPO-RAs dosage at stop.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of patients' characteristics in term of: biological and clinical features, disease duration at the beginning of TPO-RAs, number and type of therapy lines preceding TPO-RAs treatment, platelet levels at TPO-RAs start.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of an association between previous splenectomy and sustained response after discontinuation of treatment with TPO-RAs.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of concomitant therapies since TPO-RAs start in terms of type and duration of therapies.</measure>
    <time_frame>One year from start of recruitment.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.</description>
    <other_name>Thrombopoietin Receptor Agonists (TPO-RAs)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostin</intervention_name>
    <description>Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.</description>
    <other_name>Thrombopoietin Receptor Agonists (TPO-RAs)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by primary immune thrombocytopenia (pITP)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent according to ICH/EU/GCP and national local laws;

          -  Persistent or chronic pITP adult patients who have been treated with TPO-RAs therapy
             after failure of one or more therapy lines, splenectomy included;

          -  Age &gt; 18 years.

        Exclusion Criteria:

          -  Active malignancy;

          -  Active malignancy;

          -  HCVAb, HIVAb, HBsAg, HBcAb seropositive status;

          -  Chronic liver disease;

          -  Treatment with Rituximab less than 8 weeks before TPO-RAs start;

          -  Recent splenectomy (less than 8 weeks) before TPO-RAs start. Active malignancy;

          -  HCVAb, HIVAb, HBsAg, HBcAb seropositive status;

          -  Chronic liver disease;

          -  Treatment with Rituximab less than 8 weeks before TPO-RAs start;

          -  Recent splenectomy (less than 8 weeks) before TPO-RAs start. HCVAb, HIVAb, HBsAg,
             HBcAb seropositive status;

          -  Chronic liver disease;

          -  Treatment with Rituximab less than 8 weeks before TPO-RAs start;

          -  Recent splenectomy (less than 8 weeks) before TPO-RAs start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Gabriella Mazzucconi</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinico Umberto I, Hematology Department.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paola Fazi</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti</name>
      <address>
        <city>Asti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monia Marchetti</last_name>
    </contact>
    <investigator>
      <last_name>Monia Marchetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Vianelli</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Vianelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Palandrini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unit√† di Onco-Ematologia - Azienda Ospedaliera - Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ugo Consoli</last_name>
    </contact>
    <investigator>
      <last_name>Ugo Consoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unit√† di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1¬∞ Piano</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Medica III - Padiglione ex isolamento - Azienda Ospedale Universit√† San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Balleari</last_name>
    </contact>
    <investigator>
      <last_name>Enrico Balleari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margherita Giannoccaro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monia Carpenedo</last_name>
    </contact>
    <investigator>
      <last_name>Monia Carpenedo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Amendola</last_name>
    </contact>
    <investigator>
      <last_name>Angela Amendola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unit√† Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Rivolti</last_name>
    </contact>
    <investigator>
      <last_name>Elena Rivolti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit√† Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerio De Stefano</last_name>
    </contact>
    <investigator>
      <last_name>Valerio De Stefano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Rossi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Scaramucci</last_name>
    </contact>
    <investigator>
      <last_name>Laura Scaramucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasquale Niscola</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit√† degli studi &quot;Sapienza&quot; di Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gabriella Mazzucconi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ematologia - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Fozza</last_name>
    </contact>
    <investigator>
      <last_name>Claudio Fozza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune thrombocytopenia</keyword>
  <keyword>Primary</keyword>
  <keyword>Thrombopoietin receptor agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

